Results 231 to 240 of about 28,601 (275)
Trends in paediatric antiseizure-medication use and costs in France, 2014-2023: a nationwide population-based analysis. [PDF]
Lancet Reg Health EurNabbout R +5 more
europepmc +1 more source
Clinical case of a pregnant woman with arteriovenous malformation, hemorrhagic venous infarcts and epileptic seizures: a case report. [PDF]
J Med Case RepVasilev P, Viteva E.
europepmc +1 more source
Levetiracetam in Childhood Epilepsy
Pediatric Drugs, 2010 Levetiracetam is an antiepileptic drug that has been shown to be effective in various types of seizures, both partial and generalized. Although it is not yet well established because of the small number of studies, levetiracetam as both add-on therapy and monotherapy can be considered as an alternative to valproic acid in some pediatric patients.
VERROTTI DI PIANELLA, Alberto +4 more
openaire +3 more sources
Levetiracetam in Tardive Dyskinesia
Clinical Neuropharmacology, 2006 The aim of this study was to evaluate the effect of levetiracetam on tardive dyskinesia (TD), which is known to be a major limitation of chronic antipsychotic drug therapy, particularly with conventional antipsychotics.Sixteen patients suffering from chronic psychosis with TD were enrolled consecutively.
MECO G +7 more
openaire +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
CNS Drugs, 1997
[Symbol: see text] Levetiracetam is an ethyl analogue of the nootropic agent piracetam.[Symbol: see text] Results from rodent studies indicate that the drug may offer protection against absence, generalised and partial seizures.[Symbol: see text] Levetiracetam exhibits linear pharmacokinetics and has a wide therapeutic index.
M, Haria, J A, Balfour
openaire +4 more sources
[Symbol: see text] Levetiracetam is an ethyl analogue of the nootropic agent piracetam.[Symbol: see text] Results from rodent studies indicate that the drug may offer protection against absence, generalised and partial seizures.[Symbol: see text] Levetiracetam exhibits linear pharmacokinetics and has a wide therapeutic index.
M, Haria, J A, Balfour
openaire +4 more sources
Reactions Weekly, 2019
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes.
+6 more sources
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes.
+6 more sources
Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial [PDF]
Lancet, The, 2019 Background Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial
Carrol Gamble +2 more
exaly +2 more sources
Drugs of Today, 2007
Levetiracetam (LEV) is a broad-spectrum antiepileptic drug that is effective against a variety of seizure types. It is a pyrridoline derivative with a very favourable pharmacokinetic profile: excellent bioavailability, linear kinetics, minimal plasma protein binding and quick achievement of steady state concentrations. It is not metabolized through the
+5 more sources
Levetiracetam (LEV) is a broad-spectrum antiepileptic drug that is effective against a variety of seizure types. It is a pyrridoline derivative with a very favourable pharmacokinetic profile: excellent bioavailability, linear kinetics, minimal plasma protein binding and quick achievement of steady state concentrations. It is not metabolized through the
+5 more sources